<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02906397</url>
  </required_header>
  <id_info>
    <org_study_id>826247 (UPCC 24216)</org_study_id>
    <nct_id>NCT02906397</nct_id>
    <nct_alias>NCT03081377</nct_alias>
  </id_info>
  <brief_title>Galunisertib (LY2157299) Plus Stereotactic Body Radiotherapy (SBRT) in Advanced Hepatocellular Carcinoma (HCC)</brief_title>
  <official_title>A Pilot Study of Galunisertib (LY2157299) Plus Stereotactic Body Radiotherapy (SBRT) in Patients With Advanced Hepatocellular Carcinoma (HCC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the safety and tolerability of galunisertib when combined with Stereotactic Body&#xD;
      Radiotherapy (SBRT) (hypofractionated radiation).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 30, 2017</start_date>
  <completion_date type="Actual">July 21, 2021</completion_date>
  <primary_completion_date type="Actual">July 21, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety based upon standard laboratory and clinical adverse event monitoring</measure>
    <time_frame>Cycle 1 Day 15 through date of progression assessed up to 90 months</time_frame>
    <description>Number of participants with treatment-related adverse events as assessed by CTCAE v4</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS) who are receiving the combination of galunisertib plus SBRT as compared to the PFS of Galunisertib alone in historical controls.</measure>
    <time_frame>Cycle 1 Day 15 through date of progression assessed up to 90 months</time_frame>
    <description>From Cycle 1 Day 1 to progression of disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>Cycle 3 Day 1 and every 8 weeks thereafter up to 90 months</time_frame>
    <description>by conventional CT and MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Cycle 1 Day 1 to death due to any cause or last patient contact alive up to 90 months</time_frame>
    <description>start of treatment to death due to any cause or last patient contact alive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inhibition of TGF-β signaling by intervention as evidenced by downstream changes in this pathway</measure>
    <time_frame>Cycle 1 Day 15 through date of progression assessed up to 90 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Promotion of anti-tumor immunity with addition of intervention to SBRT</measure>
    <time_frame>Cycle 1 Day 15 through date of progression assessed up to 90 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>ADVANCED HEPATOCELLULAR CARCINOMA (HCC)</condition>
  <arm_group>
    <arm_group_label>Experimental: Galunisertib/SBRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Galunisertib (LY2157299) 150mg by mouth twice a day on days 1-14 of 28 day cycles SBRT 18Gy, delivered in one fraction between Cycle 1 D15 and D28</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Galunisertib 150mg by mouth twice a day</intervention_name>
    <description>on days 1-14 of 28 day cycles</description>
    <arm_group_label>Experimental: Galunisertib/SBRT</arm_group_label>
    <other_name>LY2157299</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic Body Radiotherapy (SBRT)</intervention_name>
    <description>18GY delivered in one fraction between C1D15 and C1D28</description>
    <arm_group_label>Experimental: Galunisertib/SBRT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must have histologically confirmed hepatocellular carcinoma (HCC) that is&#xD;
             inoperable (where surgery is not indicated due to disease extension, co-morbidities or&#xD;
             other technical reasons)&#xD;
&#xD;
          -  ≥18 years of age and ability to understand and the willingness to sign a written&#xD;
             informed consent document. A legally authorized representative signature in the event&#xD;
             that the subject is not able to sign themselves is permitted.&#xD;
&#xD;
          -  Patients must have either not been eligible for sorafenib therapy, have failed&#xD;
             sorafenib therapy, have discontinued sorafenib therapy due to intolerable toxicity or&#xD;
             have refused sorafenib&#xD;
&#xD;
          -  ECOG performance status ≤2&#xD;
&#xD;
          -  Childs Pugh score of ≤7&#xD;
&#xD;
          -  Life expectancy of at least 12 weeks&#xD;
&#xD;
          -  Must be able to swallow tablets&#xD;
&#xD;
          -  Must be willing to comply with protocol procedures (including completion of diaries&#xD;
             and outcome measures)&#xD;
&#xD;
          -  Local or loco-regional therapy (ie surgery, radiation therapy, hepatic arterial&#xD;
             embolization, chemoembolization, radiofrequency ablation, percutaneous ethanol&#xD;
             injection or cryoablation) must have been completed ≥4 weeks prior to enrollment&#xD;
&#xD;
          -  Must be willing to undergo a pretreatment biopsy&#xD;
&#xD;
          -  A history of prior radiotherapy is permitted, as long as the prior radiated site is&#xD;
             not overlapping with the site of planned SBRT&#xD;
&#xD;
          -  Measurable disease as defined by the Response Evaluation Criteria in Solid Tumors&#xD;
             (RECIST) version 1.1&#xD;
&#xD;
          -  An index lesion measuring between 1cm-10cm that is amenable to hypofractionated&#xD;
             radiation therapy at the discretion of the treating radiation oncologist&#xD;
&#xD;
          -  Women of childbearing potential must have a negative serum pregnancy test performed at&#xD;
             screening&#xD;
&#xD;
          -  Subjects must use an approved contraceptive method (for example, intrauterine device,&#xD;
             birth control pills or barrier device) which has an expected failure rate of &lt;1%, if&#xD;
             appropriate for at least 3 months after the last dose of galunisertib.&#xD;
&#xD;
        Patients who are HIV-positive are eligible if:&#xD;
&#xD;
          -  CD4+ cell count is greater or equal to 250cells/mm3.&#xD;
&#xD;
          -  If patient is on retroviral therapy, there must be minimal interactions or&#xD;
             -overlapping toxicity of the antiretroviral therapy with the experimental cancer&#xD;
             treatment.&#xD;
&#xD;
          -  No history of non-malignancy AIDS defining conditions other than low CD4+ count.&#xD;
&#xD;
          -  Probable long-term survival with HIV if cancer were not present.&#xD;
&#xD;
          -  Must have adequate organ and hematopoietic function as defined below:&#xD;
&#xD;
        Laboratory Test Required Value Absolute neutrophil count ≥1.5 x 10^9/L Platelet count ≥100&#xD;
        x 10^9/L Hemoglobin ≥9.0 x 10^9/L Alanine transaminase ≤2.5 x ULN Aspartate&#xD;
        aminotransferase ≤2.5 x ULN Serum creatinine or CrCl ≤2.0 x ULN Total Bilirubin ≤1.5 x ULN&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any history of a serious medical or psychiatric condition that would prevent the&#xD;
             patient from signing the informed consent form&#xD;
&#xD;
          -  Pregnant or breastfeeding women.&#xD;
&#xD;
          -  Use of any other chemotherapy, radiotherapy or experimental drug within 4 weeks prior&#xD;
             to first study treatment date&#xD;
&#xD;
          -  A history of radiotherapy that, in the opinion of the investigator, would render SBRT&#xD;
             unsafe to administer&#xD;
&#xD;
          -  Those who have not recovered from adverse events ≤ grade 1 secondary to therapy&#xD;
             administered &gt;4 weeks prior to first study treatment date, with the exception of&#xD;
             stable grade 2 neuropathy&#xD;
&#xD;
          -  Subjects may not receive concomitant anticancer agents. Antiviral agents aimed at&#xD;
             treating infectious hepatitis are permitted&#xD;
&#xD;
          -  History of or suspected hypersensitivity to radiation or to galunisertib&#xD;
&#xD;
          -  Uncontrolled ascites&#xD;
&#xD;
          -  Subjects with a history of or evidence of cardiac disease during screening, defined as&#xD;
             any one of the following: myocardial infarction within 6 months prior to study entry,&#xD;
             unstable angina pectoris, New York Heart Association Class III/IV congestive heart&#xD;
             failure, uncontrolled hypertension.&#xD;
&#xD;
          -  Subjects with a documented major ECG abnormalities (not responding to medical&#xD;
             treatments) or not clinically stable for at least 6 months.&#xD;
&#xD;
          -  Subjects with major abnormalities documented by ECHO with Doppler (for example,&#xD;
             moderate or severe heart valve function defect) that is not stable for at least 6&#xD;
             months.. Note: Left ventricular [LV] ejection fraction &lt;50% is allowed only if&#xD;
             clinically stable for at least 6 months (evaluation based on the institutional lower&#xD;
             limit of normal).&#xD;
&#xD;
          -  Subjects with a predisposition toward developing aneurysms of the ascending aorta or&#xD;
             aortic stress including a family history of aneurysms, Marfan Syndrome, Ehlers Danlos&#xD;
             Type IV, bicuspid aortic valve or evidence of damage to the large vessels of the heart&#xD;
             documented by previously obtained or screening CT scan/MRI&#xD;
&#xD;
          -  Subjects with uncontrolled brain metastases. Subjects with brain metastases must have&#xD;
             stable neurological status following local therapy (surgery or radiation) for at least&#xD;
             4 weeks prior to first study treatment and must be off steroids&#xD;
&#xD;
          -  Any concurrent condition requiring the continued or anticipated use of systemic&#xD;
             steroids beyond physiologic replacement dosing (excluding non-systemic inhaled,&#xD;
             topical skin and/or eye drop-containing corticosteroids) or immunosuppressive therapy&#xD;
             (excludes low-dose methotrexate). All other systemic corticosteroids above physiologic&#xD;
             replacement dosing must be discontinued at least 4 weeks prior to first study&#xD;
             treatment&#xD;
&#xD;
          -  Active drug or alcohol use or dependence as documented in the chart that, in the&#xD;
             opinion of the investigator, would interfere with adherence to study requirements&#xD;
&#xD;
          -  A second primary malignancy that, in the judgment of the investigator, may affect the&#xD;
             interpretation of results&#xD;
&#xD;
          -  Prior malignancies. Patients with carcinoma in-situ of any origin and patients with&#xD;
             prior malignancies who are in remission and whose likelihood of recurrence is very low&#xD;
             (such as basal cell carcinoma) as judged by the Lilly clinical research physician&#xD;
             (CRP), are eligible.&#xD;
&#xD;
          -  Any illness or condition that in the opinion of the investigator may affect the safety&#xD;
             of the subject or the evaluation of any study endpoint&#xD;
&#xD;
          -  Any other conditions judged by the investigator that would limit the evaluation of the&#xD;
             subject&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kim Reiss Binder, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Abramson Cancer Center of the University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Abramson Cancer Center of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 15, 2016</study_first_submitted>
  <study_first_submitted_qc>September 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2016</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

